Reply

Inês Coelho-Costa¹, Rita Rodrigues¹, Manuel Falcão^{1

2}

Affiliations

¹ Ophthalmology Department, Unidade de Saúde Local de São João, Porto, Portugal.
² Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal.

Inês Coelho-Costa et al. Retina. 2025.

. 2025 Oct 1;45(10):80-81.

doi: 10.1097/IAE.0000000000004549.

Inês Coelho-Costa¹, Rita Rodrigues¹, Manuel Falcão^{1

2}

¹ Ophthalmology Department, Unidade de Saúde Local de São João, Porto, Portugal.
² Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal.

No abstract available

References

1. Grajewski RS, Kaymak H. To the Editor-in-Chief. Retina 2025.
1. Rodrigues R, Falcão M. Bilateral multiple retinal serous detachments associated with FGFR inhibitor therapy. Retina 2024. doi:10.1097/IAE.0000000000004363 - DOI
1. Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 2022;23:248–258.
1. Becker B, El Hamichi S, Gold AS, Murray TG. Erdafitinib-induced secondary maculopathy. J Vitreoretin Dis 2022;6:332.
1. Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol 2016;134:855–862.